Fulgent bought CSI Laboratories, a company focused on cancer diagnostic testing for pathologists, community hospitals and patients. CSI has more than 400 unique tests and capabilities in flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization, immunohistochemistry and molecular genetics.
The acquisition will expand Fulgent’s reach past its current market in Southeastern states. Larry Weiss, MD, Fulgent’s chief medical officer, will oversee the integration of CSI’s capabilities into the Fulgent platform and company operations.
